Literature DB >> 25963173

[Pulmonary hypertension: Possible genetic causes and therapeutic options].

E Grünig1, C A Eichstaedt, N Ehlken, E Mayer, H Klose.   

Abstract

Pulmonary hypertension (PH) is a severe disease, which is usually only recognized at a late stage. It is characterized by dyspnea and right heart insufficiency. In some forms of pulmonary hypertension, such as the rare pulmonary arterial hypertension (PAH) and PAH associated with congenital heart defects, genetic factors have been identified. This article summarizes the general and supportive therapies for PH, targeted pharmaceutical treatment for PAH and non-operable chronic thromboembolic pulmonary hypertension. To achieve acceptable survival rates, it is essential to transfer patients to an expert center at an early stage for further differential diagnostics and therapy.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25963173     DOI: 10.1007/s00059-015-4230-6

Source DB:  PubMed          Journal:  Herz        ISSN: 0340-9937            Impact factor:   1.443


  64 in total

1.  Safety and efficacy of exercise training in various forms of pulmonary hypertension.

Authors:  Ekkehard Grünig; Mona Lichtblau; Nicola Ehlken; Hossein A Ghofrani; Frank Reichenberger; Gerd Staehler; Michael Halank; Christine Fischer; Hans-Jürgen Seyfarth; Hans Klose; Andreas Meyer; Stephan Sorichter; Heinrike Wilkens; Stephan Rosenkranz; Christian Opitz; Hanno Leuchte; Gabriele Karger; Rudolf Speich; Christian Nagel
Journal:  Eur Respir J       Date:  2012-02-09       Impact factor: 16.671

2.  [Mental distress and wish for psychosomatic treatment of patients with pulmonary hypertension].

Authors:  Astrid Larisch; Charlotte Neeb; Martina de Zwaan; Christian Pabst; Henning Tiede; Ardeschir Ghofrani; Karen Olsson; Marius Hoeper; Johannes Kruse
Journal:  Psychother Psychosom Med Psychol       Date:  2014-07-16

3.  The combination of exercise and respiratory training improves respiratory muscle function in pulmonary hypertension.

Authors:  Hans-Joachim Kabitz; Hinrich-Cordt Bremer; Anja Schwoerer; Florian Sonntag; Stephan Walterspacher; David Johannes Walker; Nicola Ehlken; Gerd Staehler; Wolfram Windisch; Ekkehard Grünig
Journal:  Lung       Date:  2013-12-13       Impact factor: 2.584

4.  Riociguat for the treatment of pulmonary arterial hypertension.

Authors:  Hossein-Ardeschir Ghofrani; Nazzareno Galiè; Friedrich Grimminger; Ekkehard Grünig; Marc Humbert; Zhi-Cheng Jing; Anne M Keogh; David Langleben; Michael Ochan Kilama; Arno Fritsch; Dieter Neuser; Lewis J Rubin
Journal:  N Engl J Med       Date:  2013-07-25       Impact factor: 91.245

5.  Mutations of the TGF-beta type II receptor BMPR2 in pulmonary arterial hypertension.

Authors:  Rajiv D Machado; Micheala A Aldred; Victoria James; Rachel E Harrison; Bhakti Patel; Edward C Schwalbe; Ekkehard Gruenig; Bart Janssen; Rolf Koehler; Werner Seeger; Oliver Eickelberg; Horst Olschewski; C Gregory Elliott; Eric Glissmeyer; John Carlquist; Miryoung Kim; Adam Torbicki; Anna Fijalkowska; Grzegorz Szewczyk; Jasmine Parma; Marc J Abramowicz; Nazzareno Galie; Hiroko Morisaki; Shingo Kyotani; Norifumi Nakanishi; Takayuki Morisaki; Marc Humbert; Gerald Simonneau; Olivier Sitbon; Florent Soubrier; Florence Coulet; Nicholas W Morrell; Richard C Trembath
Journal:  Hum Mutat       Date:  2006-02       Impact factor: 4.878

6.  Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial.

Authors:  Gérald Simonneau; Lewis J Rubin; Nazzareno Galiè; Robyn J Barst; Thomas R Fleming; Adaani E Frost; Peter J Engel; Mordechai R Kramer; Gary Burgess; Lorraine Collings; Nandini Cossons; Olivier Sitbon; David B Badesch
Journal:  Ann Intern Med       Date:  2008-10-21       Impact factor: 25.391

7.  Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA).

Authors:  Karen M Olsson; Marion Delcroix; H Ardeschir Ghofrani; Henning Tiede; Doerte Huscher; Rudolf Speich; Ekkehard Grünig; Gerd Staehler; Stephan Rosenkranz; Michael Halank; Matthias Held; Tobias J Lange; Juergen Behr; Hans Klose; Martin Claussen; Ralf Ewert; Christian F Opitz; C Dario Vizza; Laura Scelsi; Anton Vonk-Noordegraaf; Harald Kaemmerer; J Simon R Gibbs; Gerry Coghlan; Joanna Pepke-Zaba; Uwe Schulz; Matthias Gorenflo; David Pittrow; Marius M Hoeper
Journal:  Circulation       Date:  2013-09-30       Impact factor: 29.690

8.  Exercise training in pulmonary arterial hypertension associated with connective tissue diseases.

Authors:  Ekkehard Grünig; Felicitas Maier; Nicola Ehlken; Christine Fischer; Mona Lichtblau; Norbert Blank; Christoph Fiehn; Frank Stöckl; Felix Prange; Gerd Staehler; Frank Reichenberger; Henning Tiede; Michael Halank; Hans-Jürgen Seyfarth; Simone Wagner; Christian Nagel
Journal:  Arthritis Res Ther       Date:  2012-06-18       Impact factor: 5.156

9.  Hemodynamic and clinical onset in patients with hereditary pulmonary arterial hypertension and BMPR2 mutations.

Authors:  Nicole Pfarr; Justyna Szamalek-Hoegel; Christine Fischer; Katrin Hinderhofer; Christian Nagel; Nicola Ehlken; Henning Tiede; Horst Olschewski; Frank Reichenberger; Ardeschir H A Ghofrani; Werner Seeger; Ekkehard Grünig
Journal:  Respir Res       Date:  2011-07-29

10.  Identification of a new intronic BMPR2-mutation and early diagnosis of heritable pulmonary arterial hypertension in a large family with mean clinical follow-up of 12 years.

Authors:  Katrin Hinderhofer; Christine Fischer; Nicole Pfarr; Justyna Szamalek-Hoegel; Mona Lichtblau; Christian Nagel; Benjamin Egenlauf; Nicola Ehlken; Ekkehard Grünig
Journal:  PLoS One       Date:  2014-03-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.